The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients

Scandinavian Journal of Rheumatology

Volumn 42, Issue 1, 2013, Pages 15-19

  Van Hoogmoed, D ^a   Fransen, J ^a   Repping Wuts, H ^a   Spee, L ^a   Bleijenberg, G ^a   Van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PAIN; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; FATIGUE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUESTIONNAIRES; REGRESSION ANALYSIS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872868855     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2012.709878     Document Type: Article

References (28)

1. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17 (Pubitemid 26258765)
2. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 2006;45:885-9 (Pubitemid 43985381)
3. Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van Riel P. Persistent severe fatigue in patients with rheumatoid arthritis. J Clin Nurs 2007;16:377-83
4. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology 2010;49:1294-302
5. Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993;20:790-6 (Pubitemid 23158471)
6. Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 1998;41:2230-7 (Pubitemid 29009382)
7. Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JMGW, Wiegman O. Fatigue in rheumatoid arthritis: The role of self-efficacy and problematic social support. Br J Rheumatol 1998;37:1042-6
8. Wolfe F, Michaud K, Pincus T. Fatigue, rheumatoid arthritis, and anti-Tumor necrosis factor therapy: An investigation in 24,831 patients. J Rheumatol 2004;31:2115-20 (Pubitemid 39453228)
9. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-Tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45 (Pubitemid 36091645)
10. Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 2007;25:838-46 (Pubitemid 351166434)
11. Moreland LW, Genovese MC, Sato R, Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 2006;55:287-93
12. Netea MG, Kullberg BJ, Vonk AG, Verschueren I, Joosten LAB, van der Meer JWM. Increased voluntary exercise in mice deficient for tumour necrosis factor-Alpha and lymphotoxin-Alpha. Eur J Clin Invest 2007;37:737-41 (Pubitemid 47256174)
13. Hoving JL, Bartelds GM, Sluiter JK, Sadiraj K, Groot I, Lems WF, et al. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after 6-month course of TNF inhibitors: Prospective intervention study and partial economic evaluation. Scand J Rheumatol 2009;38:246-50
14. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37 (Pubitemid 43122183)
15. Chauffier K, Salliot C, BerenbaumF, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: A systematic review of the literature and meta-Analysis. Rheumatology (Oxford). Published online: 22 April 2011. doi:10.1093/rheumatology/ker162
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24 (Pubitemid 18091653)
17. Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease-Activity scores that include 28-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8
18. van der Heijde DM, van 't HM, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81 (Pubitemid 23102498)
19. Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JMD, van der Meer JWM, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383-92 (Pubitemid 24188056)
20. Vercoulen JHMM, Alberts M, Bleijenberg G. The Checklist Individual Strength. Gedragstherapie 1999;32:131-6
21. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel PLCM. How to assess fatigue in rheumatoid arthritis: Validity and reliability of the Checklist Individual Strength. Arthritis Rheum 2008;58:S868
22. Boers M, Jacobs JWG, Vlieland TPMV, van Riel PLCM. Consensus Dutch health assessment questionnaire. Ann Rheum Dis 2007;66:132-3 (Pubitemid 46044874)
23. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45 (Pubitemid 10164318)
24. Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997;35:785-91 (Pubitemid 27336913)
25. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-Tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebocontrolled, 52-week trial. Arthritis Rheum 2004;50:1400-11 (Pubitemid 38608061)
26. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti-Tumor necrosis factor-Alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71 (Pubitemid 37549331)
27. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004;363:1728-31 (Pubitemid 38670333)
28. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal-Antibody to tumor-necrosis-factor-Alpha (Ca2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10 (Pubitemid 24317629)